

# CERTIFICATE OF ANALYSIS No.: 2025<sup>1</sup>15864

## CLIENT

## SAMPLE \*

CBD Oil 40% ,

Sample condition: SUITABLE

Sample ID: 2502033

Sample type: Viscous liquid

Batch No.: \* DR42125010A

Work order: 2025-112533

Analysis ID: 2025\_009

Method ID: PHL\_RPC\_16C

Method SOP: MET-LAB-001-08

















Sample received: 10/01/2025

Start of analysis: 10/01/2025

End of analysis: 13/01/2025

Analyst: Valentina Malin

\* Information provided by the client.

CANNABINOID PROFILE		Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
<b>CBDV</b>	- Cannabidivarin	0.608	0.073	
<b>CBDA</b>	- Cannabidiolic acid	0.0319	0.0073	
<b>CBGA</b>	- Cannabigerolic acid	< LOQ	n/a	
<b>CBG</b>	- Cannabigerol	2.22	0.16	
<b>CBD</b>	- Cannabidiol	41.5	2.1	
<b>THCV</b>	- Tetrahydrocannabivarin	0.103	0.016	
<b>CBN</b>	- Cannabinol	0.088	0.019	
<b>Δ<sup>9</sup>-THC</b>	- Δ-9-Tetrahydrocannabinol	< LOQ	n/a	
<b>Δ<sup>8</sup>-THC</b>	- Δ-8-Tetrahydrocannabinol	< LOQ	n/a	
<b>CBL</b>	- Cannabicyclol	< LOQ	n/a	
<b>CBC</b>	- Cannabichromene	0.191	0.032	
<b>Δ<sup>9</sup>-THCA</b>	- Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	
<b>CBV</b>	- Cannabivarin	< LOQ	n/a	
<b>CBCA</b>	- Cannabichromenic acid	< LOQ	n/a	
<b>CBT</b>	- Cannabicitran	0.181	0.031	
<b>CBE</b>	- Cannabielsoin	0.127	0.029	

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w), ND = not detected, n/a = not available.


The results given herein apply only to the sample as received and tested. **Expanded Uncertainty** was calculated using coverage factor  $k = 2$ , corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.


Date issued:

13/01/2025

Approved by:

  
mag. Valentina Malin  
Analytical Laboratory Manager

Authorized by:

  
dr. Boštjan Jančar  
Chief Technology Officer

End of Certificate